AbbVie Inc.
ABBV
$245.56
$1.760.72%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 10.39% | 9.50% | 8.57% | 7.40% | 6.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.39% | 9.50% | 8.57% | 7.40% | 6.05% |
| Cost of Revenue | 4.45% | 5.68% | 4.00% | 2.22% | -0.23% |
| Gross Profit | 12.78% | 11.06% | 10.49% | 9.62% | 8.82% |
| SG&A Expenses | 1.15% | -2.37% | -3.23% | -3.27% | 7.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 100.00% | -242.86% | -242.86% | -118.34% | -118.34% |
| Total Operating Expenses | 5.22% | 4.27% | 2.91% | 1.93% | 4.94% |
| Operating Income | 21.17% | 20.85% | 21.20% | 19.82% | 8.45% |
| Income Before Tax | 187.10% | 64.96% | 77.53% | -76.93% | -57.12% |
| Income Tax Expenses | 421.59% | 501.72% | 514.74% | -135.61% | -143.18% |
| Earnings from Continuing Operations | 67.49% | -13.37% | -1.24% | -53.34% | -29.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 25.00% | 25.00% | 12.50% | 36.36% | 27.27% |
| Net Income | 67.69% | -13.35% | -1.22% | -53.38% | -29.52% |
| EBIT | 21.17% | 20.85% | 21.20% | 19.82% | 8.45% |
| EBITDA | 13.25% | 13.07% | 13.35% | 12.86% | 4.73% |
| EPS Basic | 68.22% | -13.57% | -1.34% | -53.76% | -29.71% |
| Normalized Basic EPS | 22.81% | 21.82% | 20.86% | 17.69% | 5.46% |
| EPS Diluted | 68.53% | -13.69% | -1.59% | -54.01% | -29.95% |
| Normalized Diluted EPS | 22.80% | 21.79% | 20.85% | 17.68% | 5.47% |
| Average Basic Shares Outstanding | 0.10% | 0.08% | 0.06% | -0.06% | -0.03% |
| Average Diluted Shares Outstanding | 0.11% | 0.11% | 0.06% | -0.06% | -0.04% |
| Dividend Per Share | 5.56% | 5.64% | 5.72% | 5.81% | 5.55% |
| Payout Ratio | -0.37% | 0.22% | 0.07% | 1.26% | 0.49% |